Cisplatin plus VP16-213 in refractory ovarian carcinoma.
Twenty-five patients with FIGO stage III and IV ovarian carcinoma were treated with cisplatin plus VP16-213 chemotherapy as the second, third, or fourth line of therapy. There were two (8%) partial responses, 18 with stable disease and five with progression of disease. Neurotoxicity was observed in all patients, with two patients developing severe paresthesias and difficulty in walking.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D005047:Etoposide; D002945:Cisplatin